NPACT- Naturally occuring Plant based Anticancerous Compound-Activity-Target DataBase
a

Compound: Resveratrol

TargetsGene NameGene IDCancerCell LinesIC50ED50EC50GI50RemarkReferences
CASP3caspase 3, apoptosis-related cysteine peptidase836NeuroblastomaSK-N-AS----With the treatment of resveratrol Cancer cell showed increased activity of Caspase-3 with increasing drug concentration, suggesting that this downstream component in the intrinsic apoptotic pathway are activated in response to resveratrol treatment.17785572
CASP3caspase 3, apoptosis-related cysteine peptidase836NeuroblastomaNGP----With the treatment of resveratrol Cancer cell showed increased activity of Caspase-3 with increasing drug concentration, suggesting that this downstream component in the intrinsic apoptotic pathway are activated in response to resveratrol treatment.17785572
CASP3caspase 3, apoptosis-related cysteine peptidase836NeuroblastomaSH-SY5Y----With the treatment of resveratrol Cancer cell showed increased activity of Caspase-3 with increasing drug concentration, suggesting that this downstream component in the intrinsic apoptotic pathway are activated in response to resveratrol treatment.17785572
CASP8caspase 8, apoptosis-related cysteine peptidase841NeuroblastomaSK-N-AS----Procaspase-8 was cleaved in SK-N-AS cells in a time-dependent manner indicated by the appearance of 43- and 41-kDa intermediate cleavage products and an 18-kDa active product17785572
CASP9caspase 9, apoptosis-related cysteine peptidase842NeuroblastomaSK-N-AS----With the treatment of resveratrol cancer cell showed increased activity of Caspase-9 with increasing drug concentration, suggesting that this downstream component in the intrinsic apoptotic pathway are activated in response to resveratrol treatment.17785572
CASP9caspase 9, apoptosis-related cysteine peptidase842NeuroblastomaNGP----With the treatment of resveratrol cancer cell showed increased activity of Caspase-9 with increasing drug concentration, suggesting that this downstream component in the intrinsic apoptotic pathway are activated in response to resveratrol treatment.17785572
CASP9caspase 9, apoptosis-related cysteine peptidase842NeuroblastomaSH-SY5Y----With the treatment of resveratrol cancer cell showed increased activity of Caspase-9 with increasing drug concentration, suggesting that this downstream component in the intrinsic apoptotic pathway are activated in response to resveratrol treatment.17785572
CCNB1cyclin B1891Breast adenocarcinomaMCF-7----Cyclin B1 expression was detectable in and decreased in all cell lines after treatment with resveratrol.11895924
CCNB1cyclin B1891Colon CancerSW-480----Cyclin B1 expression was detectable in and decreased in all cell lines after treatment with resveratrol.11895924
CCNB1cyclin B1891Esophageal AdenocarcinomaSeg-1----Cyclin B1 expression was detectable in and decreased in all cell lines after treatment with resveratrol.11895924
CCNB1cyclin B1891Esophageal squamous carcinomaHCE7----Cyclin B1 expression was detectable in and decreased in all cell lines after treatment with resveratrol.11895924
CCNB1cyclin B1891Human promyelocytic leukemiaHL-60----Cyclin B1 expression was detectable in and decreased in all cell lines after treatment with resveratrol.11895924
CCND1cyclin D1595Colon CancerSW-480----Western blot analysis demonstrated that cyclin A and cyclin B1 expression levels did not change initially but decreased after 24 and 48 h of treatment. Interestingly, cyclin D1 expression decreased after only 2 h of treatment and remained diminished after 24 and 48 h of treatment. A lower dose of resveratrol near the IC50 value (100 M) also decreased cyclin D1 expression significantly at 2, 6, 24, and 48 h.11895924
CTNNBIP1catenin, beta interacting protein 156998Colon CancerSW-480----Beta-Catenin is involved in both colon carcinogenesis and cyclin D1 transcriptional regulation.Cellular extracts were evaluated for -catenin expression after 2, 6, 24, and 48 h of treatment. Western blot analysis demonstrated that Beta-catenin expression did not change initially but decreased after 24 and 48 h of treatment.11895924
CycACyclin A39340Colon CancerSW-480----Western blot analysis demonstrated that cyclin A and cyclin B1 expression levels did not change initially but decreased after 24 and 48 h of treatment. Interestingly, cyclin D1 expression decreased after only 2 h of treatment and remained diminished after 24 and 48 h of treatment. A lower dose of resveratrol near the IC50 value (100 M) also decreased cyclin D1 expression significantly at 2, 6, 24, and 48 h.11895924
CYCScytochrome c54205NeuroblastomaNGP----Cytochrome c was released into the cytosol at different times after initiating drug treatment. In NGP cells, cytochrome c release occurred after 24 to 48 h17785572
CYCScytochrome c54205NeuroblastomaSH-SY5Y----Cytochrome c was released into the cytosol at different times after initiating drug treatment. In SH-SY5Y cells, cytochrome c release occurred after 24 to 48 h17785572
CYCScytochrome c54205NeuroblastomaSK-N-AS----Cytochrome c was released into the cytosol at different times after initiating drug treatment. In SK-N-AS cells, cytochrome c was already detectable in the cytosolic fraction after 2 h17785572
DIABLOdiablo, IAP-binding mitochondrial protein56616NeuroblastomaSK-N-AS----Smac/Diablo was released from the mitochondria with the treatment of compound.17785572
DIABLOdiablo, IAP-binding mitochondrial protein56616NeuroblastomaNGP----Smac/Diablo was released from the mitochondria with the treatment of compound.17785572
DIABLOdiablo, IAP-binding mitochondrial protein56616NeuroblastomaSH-SY5Y----Smac/Diablo was released from the mitochondria with the treatment of compound.17785572

 






Copyright © 2012. Subhash M. Agagrwal. All Rights Reserved.